Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | FABP3 | P05413 | 1/20 | 0.37 |
| ▸ | FABP4 | P15090 | 1/20 | 0.37 |
| ▸ | PRNP | P04156 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31125623 | 1.00 | ALDH1A1 (0.68) | ALDH1A1SMN1; SMN2MAPK1POLBCYP3A4 | |
| SCHEMBL8686340 | 0.84 | SMN1; SMN2 (0.80) | ALDH1A1SMN1; SMN2MAPK1POLBCYP3A4 | |
| SCHEMBL5391695 | 0.83 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2MAPK1POLBCYP3A4 | |
| SCHEMBL2381068 | 0.83 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2MAPK1POLBCYP1A2 | |
| SCHEMBL4746949 | 0.81 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2MAPK1CYP3A4ACHE | |
| SCHEMBL22445800 | 0.81 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2MAPK1POLBCYP3A4 | |
| SCHEMBL14353515 | 0.81 | POLB (0.69) | ALDH1A1SMN1; SMN2MAPK1POLBCYP3A4 | |
| SCHEMBL3340047 | 0.81 | SMN1; SMN2 (1.00) | ALDH1A1SMN1; SMN2MAPK1POLBCYP3A4 | |
| SCHEMBL4698528 | 0.81 | SMN1; SMN2 (0.66) | ALDH1A1SMN1; SMN2MAPK1POLBCYP3A4 | |
| SCHEMBL31633618 | 0.81 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2MAPK1POLBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1085200-C | Process for producing dimethylamine | MITSUBISHI NITTO K K (JP) | 2002-05-22 | — | — | CN | claimed |
| EP-0744395-B1 | PROCESS FOR PRODUCING DIMETHYLAMINE | MITSUBISHI RAYON CO (JP) | 2001-10-31 | — | — | EP | claimed |
| US-20240270742-A1 | SUBSTITUTED AMINO ACIDS AS INTEGRIN INHIBITORS | PLIANT THERAPEUTICS INC (US) | 2024-08-15 | — | — | US | disclosed |
| US-11952376-B2 | Substituted amino acids as integrin inhibitors | PLIANT THERAPEUTICS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| WO-2022133588-A1 | RNA VIRUS INHIBITOR COMPOUNDS AND USES THEREOF | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2022-06-30 | — | — | WO | disclosed |
| US-20220144829-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2022-05-12 | — | — | US | disclosed |
| US-11180494-B2 | Substituted amino acids as integrin inhibitors | PLIANT THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| EP-3863711-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2021-08-18 | — | — | EP | disclosed |
| CN-113195053-A | Amino acid compounds and methods of use | 普利安特治疗公司 | 2021-07-30 | — | — | CN | disclosed |
| US-20200109141-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2020-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144829-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA1, ITGAL | ALDH1A1 1981/4885SMN1; SMN2 2699/4885MAPK1 808/4885 |
| US-20200109141-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA1, ITGAL | ALDH1A1 1981/4885SMN1; SMN2 2699/4885MAPK1 808/4885 |
| US-11952376-B2 | Substituted amino acids as integrin inhibitors | ITGB6, ITGA1, ITGB1 | ALDH1A1 2168/4885SMN1; SMN2 2223/4885MAPK1 1100/4885 |
| US-11180494-B2 | Substituted amino acids as integrin inhibitors | ITGB6, ITGA1, ITGB1 | ALDH1A1 2168/4885SMN1; SMN2 2223/4885MAPK1 1100/4885 |
| US-20240270742-A1 | SUBSTITUTED AMINO ACIDS AS INTEGRIN INHIBITORS | ITGB6, ITGA1, ITGB1 | ALDH1A1 2168/4885SMN1; SMN2 2223/4885MAPK1 1100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.